(4aS,5R,7aS)-7a-[2-fluoro-5-[3-(trifluoromethyl)-2H-pyridin-1-yl]phenyl]-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-2-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (4aS,5R,7aS)-7a-[2-fluoro-5-[3-(trifluoromethyl)-2H-pyridin-1-yl]phenyl]-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-2-amine
• 化学式: C₁₉H₁₉F₄N₃OS
• 分子量: 413.4
• InChiKey: JKFSUMCFHHKACF-PZDGAKPMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  76.2
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Fused Aminodihydrothiazine Derivatives
  申请人：Dimopoulos Paschalis

  公开号：US20140011802A1

  公开（公告）日：2014-01-09

  The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein R is hydrogen or C 1-6 alkyl, optionally substituted by one to five halogen atoms; n is 0, 1, 2 or 3; Ar is phenyl or a 5- or 6-membered heteroaromatic group containing 1, 2 or 3 N atoms, which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl, —CN, C 1-6 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C-6 alkoxy, C 3-6 cycloalkoxy and pyrazine, where C 1-6 alkyl and C 1-6 alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease 1 caused by Aβ and typified by Alzheimer-type dementia.

  本发明涉及一种公式（I）的融合氨基二氢噻唑衍生物：其中R是氢或C1-6烷基，可选地被一个至五个卤素原子取代；n是0、1、2或3；Ar是苯基或含1、2或3个N原子的5或6元杂芳族基团，其中Ar可选地被一个至三个选自卤素、羟基、—CN、C1-6烷基、C2-3烯基、C2-3炔基、C-6烷氧基、C3-6环烷氧基和吡嗪的取代基取代，其中C1-6烷基和C1-6烷氧基可选地被一个至三个卤素原子取代；以及药用可接受的盐；该化合物具有Aβ生成抑制效果或BACE1抑制效果，并且可用作预防或治疗由Aβ引起的神经退行性疾病1的预防或治疗剂，该疾病以阿尔茨海默症型痴呆为典型。
• US8822455B2
  申请人：——

  公开号：US8822455B2

  公开（公告）日：2014-09-02